Posted by Michael Wonder on 20 Aug 2024
Fasenra approved in China for the treatment of severe eosinophilic asthma
20 August 2024 - Approval based on MIRACLE Phase 3 trial demonstrating a significant and clinically meaningful reduction in asthma exacerbations and improvement in asthma symptom control.
AstraZeneca’s Fasenra (benralizumab) has been approved in China by the country’s National Medical Products Association for the maintenance treatment of patients 12 years of age and older with severe eosinophilic asthma.
